Home>Research>Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUIINE): a phase 3, multicentre, open-label, randomised trial

US Oncology Research Publications

« Back to All Resources

Other/Unspecified
Treatment

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUIINE): a phase 3, multicentre, open-label, randomised trial